Cardiomyopathy Trial, Recruiting (NCT05212792)

Cardiomyopathy Trial, Recruiting NCT05212792 Sponsor: University of British Columbia Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT05212792 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You received a COVID-19 vaccine and afterwards developed one of these conditions: Guillain-Barré Syndrome (a nerve disorder), a serious blood clotting and low platelet condition (sometimes called VITT or TTS), or inflammation of the heart or its surrounding lining (myocarditis/pericarditis)
You received a COVID-19 vaccine and did not develop any of the conditions listed above (this trial also needs participants who had no serious side effects after vaccination)

Who may not be able to join:

You have not received any COVID-19 vaccine
You are unable to read, understand, and agree to the terms of participation in the study yourself (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bruce Carleton, PharmD, University of British Columbia

Phone: 1.877.878.4131

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05212792

Sponsor: University of British Columbia

Phase: Not Applicable

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: 1.877.878.4131

More information: https://clinicaltrials.gov/study/NCT05212792

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You received a COVID-19 vaccine and afterwards developed one of these conditions: Guillain-Barré Syndrome (a nerve disorder), a serious blood clotting and low platelet condition (sometimes called VITT or TTS), or inflammation of the heart or its surrounding lining (myocarditis/pericarditis)
You received a COVID-19 vaccine and did not develop any of the conditions listed above (this trial also needs participants who had no serious side effects after vaccination)

Who may not be able to join:

You have not received any COVID-19 vaccine
You are unable to read, understand, and agree to the terms of participation in the study yourself (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of British Columbia

Registry

ClinicalTrials.gov

Start date

24 June 2022

Est. completion

1 December 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Determine specific genetic factors associated with particular COVID-19 vaccine-induced Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov